These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35968648)

  • 1. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants.
    Li Z; Lin C; Zhou J; Cai X; Zhu X; Hu S; Lv F; Yang W; Ji L
    Expert Opin Investig Drugs; 2022 Sep; 31(9):957-964. PubMed ID: 35968648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
    Zhao L; Meng J; Bai X; Zhang D; Yang X; Yang Y; Cai G; Liu X
    Eur J Med Res; 2024 Jul; 29(1):363. PubMed ID: 38997754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
    Yang W; Cai X; Zhang S; Han X; Ji L
    Diabetes Metab Res Rev; 2021 Mar; 37(3):e3391. PubMed ID: 32741073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
    Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
    J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L; Zheng XQ; Liao XX
    Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
    Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
    Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
    J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
    Baksh S; Wen J; Mansour O; Chang HY; McAdams-DeMarco M; Segal JB; Ehrhardt S; Alexander GC
    Sci Rep; 2021 Aug; 11(1):16637. PubMed ID: 34404825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
    Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
    Morieri ML; Bonora BM; Longato E; Di Camilo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2020 Oct; 22(10):1925-1934. PubMed ID: 32691492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Gong Y; Bai X; Zhang D; Yang X; Qin Z; Yang Y; Zhou Y; Meng J; Liu X
    Lipids Health Dis; 2024 May; 23(1):157. PubMed ID: 38796440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
    Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
    Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
    Liu X; Men P; Wang B; Cai G; Zhao Z
    Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer.
    Saito A; Kitayama J; Horie H; Koinuma K; Kawashima R; Ohzawa H; Yamaguchi H; Kawahira H; Mimura T; Lefor AK; Sata N
    Cancer Res Commun; 2021 Nov; 1(2):106-114. PubMed ID: 36860286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
    Sugiyama S; Yamamoto T; Aoyama Y
    J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.